Cargando…
Drug switching in axial spondyloarthritis patients in Germany – a social listening analysis
BACKGROUND: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease which primarily affects the axial skeleton resulting in chronic back pain and stiffness. According to the guideline, the first-line treatment includes non-steroidal anti-inflammatory drugs (NSAIDs), conventional synthetic...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10411271/ https://www.ncbi.nlm.nih.gov/pubmed/37565049 http://dx.doi.org/10.1177/1759720X231187189 |
_version_ | 1785086628640849920 |
---|---|
author | Kahn, Maria Papukchieva, Steffeni Fehr, Axel Eberl, Markus Rösler, Berenice Veit, Justyna Friedrich, Benjamin Poddubnyy, Denis |
author_facet | Kahn, Maria Papukchieva, Steffeni Fehr, Axel Eberl, Markus Rösler, Berenice Veit, Justyna Friedrich, Benjamin Poddubnyy, Denis |
author_sort | Kahn, Maria |
collection | PubMed |
description | BACKGROUND: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease which primarily affects the axial skeleton resulting in chronic back pain and stiffness. According to the guideline, the first-line treatment includes non-steroidal anti-inflammatory drugs (NSAIDs), conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and non-pharmacological treatment. Second line treatment involves biological disease-modifying antirheumatic drugs (bDMARDs) such as tumour necrosis factor and interleukin-17 inhibitors. OBJECTIVES: The aim of this social media listening research project was to analyse switches of medication and the reasons thereof to gain valuable insights into real-life journeys of patients suffering from axSpA. METHODS: Publicly available posts in German-speaking disease-specific forums were scanned for disease-specific keywords and commonly used drugs by axSpA patients on the Permea platform. Posts containing at least two key words were selected and switches between medications were manually labelled. A total of 287 scraped posts between 01 July 2010 and 04 Feb 2022 were analysed. RESULTS: The largest group of described medication switches was initially using bDMARDs. Switches to a different bDMARD, termination of medication and switches to glucocorticoids were most frequently named. Patients on NSAIDs switched to glucocorticoids, a different NSAID or bDMARD, whereas patients on csDMARDs most frequently changed to bDMARDs. In all medication groups the main reason for switching was insufficient efficacy and side effects. Additionally, for the medication groups bDMARDs, csDMARDs and corticosteroids, pregnancy and lactation were given as a reason for switching, whereas patients in the NSAID group never mentioned pregnancy and breastfeeding as a reason for switching treatment. CONCLUSION: Our analysis shows medication switches based on real-life patient experiences shared with peers in a social listening setting. We also show medication switches differing from advised guidelines. Gathering real-life insights into patients’ journey dealing with chronic diseases allows us to understand, and thereby improve patient care and treatment. |
format | Online Article Text |
id | pubmed-10411271 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-104112712023-08-10 Drug switching in axial spondyloarthritis patients in Germany – a social listening analysis Kahn, Maria Papukchieva, Steffeni Fehr, Axel Eberl, Markus Rösler, Berenice Veit, Justyna Friedrich, Benjamin Poddubnyy, Denis Ther Adv Musculoskelet Dis Original Research BACKGROUND: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease which primarily affects the axial skeleton resulting in chronic back pain and stiffness. According to the guideline, the first-line treatment includes non-steroidal anti-inflammatory drugs (NSAIDs), conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and non-pharmacological treatment. Second line treatment involves biological disease-modifying antirheumatic drugs (bDMARDs) such as tumour necrosis factor and interleukin-17 inhibitors. OBJECTIVES: The aim of this social media listening research project was to analyse switches of medication and the reasons thereof to gain valuable insights into real-life journeys of patients suffering from axSpA. METHODS: Publicly available posts in German-speaking disease-specific forums were scanned for disease-specific keywords and commonly used drugs by axSpA patients on the Permea platform. Posts containing at least two key words were selected and switches between medications were manually labelled. A total of 287 scraped posts between 01 July 2010 and 04 Feb 2022 were analysed. RESULTS: The largest group of described medication switches was initially using bDMARDs. Switches to a different bDMARD, termination of medication and switches to glucocorticoids were most frequently named. Patients on NSAIDs switched to glucocorticoids, a different NSAID or bDMARD, whereas patients on csDMARDs most frequently changed to bDMARDs. In all medication groups the main reason for switching was insufficient efficacy and side effects. Additionally, for the medication groups bDMARDs, csDMARDs and corticosteroids, pregnancy and lactation were given as a reason for switching, whereas patients in the NSAID group never mentioned pregnancy and breastfeeding as a reason for switching treatment. CONCLUSION: Our analysis shows medication switches based on real-life patient experiences shared with peers in a social listening setting. We also show medication switches differing from advised guidelines. Gathering real-life insights into patients’ journey dealing with chronic diseases allows us to understand, and thereby improve patient care and treatment. SAGE Publications 2023-08-08 /pmc/articles/PMC10411271/ /pubmed/37565049 http://dx.doi.org/10.1177/1759720X231187189 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Kahn, Maria Papukchieva, Steffeni Fehr, Axel Eberl, Markus Rösler, Berenice Veit, Justyna Friedrich, Benjamin Poddubnyy, Denis Drug switching in axial spondyloarthritis patients in Germany – a social listening analysis |
title | Drug switching in axial spondyloarthritis patients in Germany – a social listening analysis |
title_full | Drug switching in axial spondyloarthritis patients in Germany – a social listening analysis |
title_fullStr | Drug switching in axial spondyloarthritis patients in Germany – a social listening analysis |
title_full_unstemmed | Drug switching in axial spondyloarthritis patients in Germany – a social listening analysis |
title_short | Drug switching in axial spondyloarthritis patients in Germany – a social listening analysis |
title_sort | drug switching in axial spondyloarthritis patients in germany – a social listening analysis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10411271/ https://www.ncbi.nlm.nih.gov/pubmed/37565049 http://dx.doi.org/10.1177/1759720X231187189 |
work_keys_str_mv | AT kahnmaria drugswitchinginaxialspondyloarthritispatientsingermanyasociallisteninganalysis AT papukchievasteffeni drugswitchinginaxialspondyloarthritispatientsingermanyasociallisteninganalysis AT fehraxel drugswitchinginaxialspondyloarthritispatientsingermanyasociallisteninganalysis AT eberlmarkus drugswitchinginaxialspondyloarthritispatientsingermanyasociallisteninganalysis AT roslerberenice drugswitchinginaxialspondyloarthritispatientsingermanyasociallisteninganalysis AT veitjustyna drugswitchinginaxialspondyloarthritispatientsingermanyasociallisteninganalysis AT friedrichbenjamin drugswitchinginaxialspondyloarthritispatientsingermanyasociallisteninganalysis AT poddubnyydenis drugswitchinginaxialspondyloarthritispatientsingermanyasociallisteninganalysis |